Franklin Resources Inc. Has $1.87 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Franklin Resources Inc. lowered its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 58.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 154,367 shares of the company’s stock after selling 217,863 shares during the period. Franklin Resources Inc.’s holdings in Elanco Animal Health were worth $1,869,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in Elanco Animal Health during the third quarter valued at approximately $35,000. Jones Financial Companies Lllp grew its stake in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after buying an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. raised its holdings in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock worth $60,000 after acquiring an additional 3,411 shares during the period. MRP Capital Investments LLC acquired a new position in Elanco Animal Health during the 4th quarter worth $61,000. Finally, Blue Trust Inc. boosted its holdings in Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after acquiring an additional 1,894 shares during the period. Institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the acquisition, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Down 0.8 %

ELAN opened at $8.64 on Monday. Elanco Animal Health Incorporated has a fifty-two week low of $8.03 and a fifty-two week high of $18.80. The company has a market capitalization of $4.29 billion, a P/E ratio of 21.60, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm’s fifty day moving average price is $10.59 and its two-hundred day moving average price is $12.02.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the firm posted $0.08 earnings per share. Elanco Animal Health’s revenue was down 1.4% on a year-over-year basis. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on ELAN. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler reduced their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.